RU2019107667A3 - - Google Patents

Download PDF

Info

Publication number
RU2019107667A3
RU2019107667A3 RU2019107667A RU2019107667A RU2019107667A3 RU 2019107667 A3 RU2019107667 A3 RU 2019107667A3 RU 2019107667 A RU2019107667 A RU 2019107667A RU 2019107667 A RU2019107667 A RU 2019107667A RU 2019107667 A3 RU2019107667 A3 RU 2019107667A3
Authority
RU
Russia
Application number
RU2019107667A
Other languages
Russian (ru)
Other versions
RU2019107667A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019107667A publication Critical patent/RU2019107667A/ru
Publication of RU2019107667A3 publication Critical patent/RU2019107667A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2019107667A 2016-10-05 2017-10-03 Спироциклические соединения RU2019107667A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404668P 2016-10-05 2016-10-05
US62/404,668 2016-10-05
PCT/US2017/054865 WO2018067512A1 (en) 2016-10-05 2017-10-03 Spirocyclic compounds

Publications (2)

Publication Number Publication Date
RU2019107667A RU2019107667A (ru) 2020-11-06
RU2019107667A3 true RU2019107667A3 (https=) 2021-01-27

Family

ID=61831517

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019107667A RU2019107667A (ru) 2016-10-05 2017-10-03 Спироциклические соединения

Country Status (13)

Country Link
US (2) US10934304B2 (https=)
EP (1) EP3523306A4 (https=)
JP (2) JP6949952B2 (https=)
KR (1) KR20190075931A (https=)
CN (1) CN109890827A (https=)
AU (1) AU2017339890A1 (https=)
BR (1) BR112019005305A2 (https=)
CA (1) CA3037064A1 (https=)
IL (1) IL265752A (https=)
MX (1) MX2019003938A (https=)
RU (1) RU2019107667A (https=)
TW (1) TW201817732A (https=)
WO (1) WO2018067512A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58514B1 (sr) 2012-06-13 2019-04-30 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX379622B (es) 2015-04-03 2025-03-11 Recurium Ip Holdings Llc Compuestos espirociclicos
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
HRP20241288T1 (hr) 2018-05-04 2024-12-06 Incyte Corporation Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
CN112654396B (zh) * 2018-09-07 2025-07-01 默克专利股份公司 5-吗啉-4-基-吡唑并[4,3-b]吡啶衍生物
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7832891B2 (ja) 2019-12-04 2026-03-18 インサイト・コーポレイション Fgfr阻害剤の誘導体
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN110922421B (zh) * 2019-12-17 2023-05-05 安徽英特美科技有限公司 一种n-甲基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
AU2024374279A1 (en) * 2023-10-31 2026-03-12 C4 Therapeutics, Inc. Compounds for the degradation of mutant braf

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA84930C2 (ru) 2004-05-14 2008-12-10 Вертекс Фармасьютикалс Инкорпорейтед Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
KR101417136B1 (ko) * 2005-12-13 2014-08-07 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 폴리사이클릭 인다졸 유도체 및 이를 포함하는 약제학적 조성물
WO2008063609A2 (en) 2006-11-17 2008-05-29 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
CA2691417A1 (en) * 2007-06-18 2008-12-24 Schering Corporation Heterocyclic compounds and use thereof as erk inhibitors
EP2318388A2 (en) 2008-07-23 2011-05-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
EP3296398A1 (en) 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
US8664213B2 (en) * 2011-08-29 2014-03-04 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as HIV attachment inhibitors
CN103130775B (zh) 2011-11-22 2015-09-30 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
US8987264B2 (en) 2012-11-09 2015-03-24 Bristol-Myers Squibb Company 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C
US9447026B2 (en) 2013-03-14 2016-09-20 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
US9879029B2 (en) 2014-12-22 2018-01-30 Eli Lilly And Company ERK inhibitors
CN105732636B (zh) * 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
MX379622B (es) 2015-04-03 2025-03-11 Recurium Ip Holdings Llc Compuestos espirociclicos

Also Published As

Publication number Publication date
CA3037064A1 (en) 2018-04-12
TW201817732A (zh) 2018-05-16
CN109890827A (zh) 2019-06-14
EP3523306A1 (en) 2019-08-14
JP2021193138A (ja) 2021-12-23
EP3523306A4 (en) 2020-05-06
US20210115058A1 (en) 2021-04-22
WO2018067512A1 (en) 2018-04-12
MX2019003938A (es) 2019-06-10
NZ751398A (en) 2021-03-26
RU2019107667A (ru) 2020-11-06
AU2017339890A1 (en) 2019-04-11
WO2018067512A8 (en) 2018-11-01
US10934304B2 (en) 2021-03-02
IL265752A (en) 2019-06-30
JP2019534261A (ja) 2019-11-28
KR20190075931A (ko) 2019-07-01
JP6949952B2 (ja) 2021-10-13
US20200207776A1 (en) 2020-07-02
BR112019005305A2 (pt) 2019-07-02

Similar Documents

Publication Publication Date Title
CH714036A1 (https=)
RU2019107667A3 (https=)
BR202017015425U2 (https=)
BR202016021748U2 (https=)
CN303537770S (https=)
CN303538165S (https=)
CN303606456S (https=)
CN303566359S (https=)
CN303555618S (https=)
CN303538754S (https=)
CN303538723S (https=)
CN303538593S (https=)
CN303634456S (https=)
CN303538553S (https=)
CN303538541S (https=)
CN303538471S (https=)
CN303538456S (https=)
CN303538367S (https=)
CN303538295S (https=)
CN303537567S (https=)
CN303538059S (https=)
CN303537999S (https=)
CN303537853S (https=)
CN303537797S (https=)
CN303538744S (https=)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20220110